Puma Biotechnology | PBYI - Stock


Puma Biotechnology reported $9.48M in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
Agios Pharmaceuticals USD 35.75M 665K Jun/2026
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
Amgen USD 6.22B 34M Jun/2026
Biogen USD 2.38B 435.3M Jun/2026
BioMarin Pharmaceutical USD 1.78B 509.3M Jun/2026
Daiichi Sankyo JPY 692.38B 83.83B Mar/2026
Exelixis USD 28.73M 2.12M Jun/2026
Gilead Sciences USD 1.91B 140M Mar/2026
Glaxosmithkline GBP 6.16B 39M Mar/2026
Incyte USD 112.54M 3.08M Jun/2026
MacroGenics USD 9.5M 1.59M Mar/2026
Moderna USD 280M 134M Jun/2026
Novartis USD 6.22B 66M Jun/2026
Pfizer USD 9.94B 722M Jun/2026
PTC Therapeutics USD 91.35M 15.79M Jun/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 3.08B 19.3M Jun/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 904.27M 96.84M Jun/2026
Takeda JPY 1.45T 50.64B Jun/2026
TG Therapeutics USD 147.97M 18.94M Jun/2026
Ultragenyx Pharmaceutical USD 59M 4M Jun/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025
Vertex Pharmaceuticals USD 1.77B 1.6M Jun/2026